

A Review on Pharmacosomes: A Novel Vesicular Approach for Enhancement of Solubility and Permeability of Drugs.

Abdul Mannan, Iqra Fatima

Department of Pharmaceutics, Deccan School of Pharmacy

Submitted: 16-09-2022

Accepted: 26-09-2022

ABSTRACT:

Novel drug delivery system mainly consents about achieving the targeted concentration to release the drug at targeted site by using carrier system, altering the structure and microenvironment around the drug. Especially drugs which are having narrow therapeutic window are difficult to formulate, with the advantage of novel drug delivery systems like particulate, polymeric carrier, macromolecular and cellular carriers. In vesicular drug delivery system drug binds covalently to the lipid molecule by which the drug release is in a controlled manner and also drugs which are of hydrophilic or lipophilic nature can be delivered by using vesicular drug delivery systems. Both synthetic and natural drugs which are facing difficulties like low solubility and low permeability can be effectively formulated and can achieve required pharmacokinetic and pharmacodynamic parameters. In the arena of solubility enhancement, several problems are encountered. A novel approach based on lipid drug delivery system has evolved, pharmacosomes. Pharmacosomes are colloidal, nanometric size micelles, vesicles or may be in the form of hexagonal assembly of colloidal drug dispersions attached covalently to the phospholipid. Pharmacosomes are prepared by hand shaking method, ether injection, solvent evaporation method, anhydrous co-solvent lyophilization, supercritical fluid approach and other alternative methods they are characterized by complex determination, surface morphology, drug entrapment, solubility, drug lipid compatibility,

crystal state measurement, dissolution studies and in vitro drug release rate.

Keywords: phospholipid, permeability, drug phospholipid complex, covalent bond, pharmacosomes, preparation, characterization.

I. INTRODUCTION:

Novel drug delivery system (NDDS) primarily focuses on formulation, technologies, and systems for transporting a pharmaceutical compound in the body as needed to safely achieve its desired therapeutic effects. Safely novel drug delivery is far better than the conventional dosage form. Novel drug delivery system should full fill the following requirements:

Firstly, it delivers specific amount of drug at a rate directed by the needs of the body, over the period of treatment. (1,2,3)

Advantages of novel drug delivery system:

- Incorporation of therapeutic dose at controlled rate,
- Sustaining drug concentration within an optimal range,
- Optimum dose at right time and at right location,
- Efficient use of expensive drugs and excipients,
- Minimizes adverse or toxic effects,
- Freedom from frequent dose intake,
- Improved patient compliance. (4,5)



Figure 1. Different types of Pharmaceutical Carriers

VESICULAR DRUG DELIVERY SYSTEM

Systems that can improve the bioavailability of the drug and the reduction in toxicity by drug targeting to the specific site. Bingham pioneered the biologic origin of vesicular systems in 1965, and hence named them Bingham bodies. As a consequence, a large account of vesicular systems like liposome, noisome, and pharmacosome came into existence Drug carriers release the drug in systemic circulation in a controlled manner. This can be attained either by slow release of drug over a long period of time or by actuated release at the drug target by some stimulants such as changes in pH, application of heat, and activation by light.

Especially, in the case of drugs with poor water solubility and/or membrane permeability, drug carriers are used to improve their pharmacokinetic and the bioavailability. The pharmaceutical carriers are classified as particulate type, polymeric, macromolecular and cellular carriers. The different methods present in binding the drug with carrier include adsorption, encapsulation and covalent bonding. Different type drug carriers utilize different type of attachment methods. (6,7,8)

ADVANTAGES OF VESICULAR DRUG DELIVERY SYSTEM

- They extend the presence of the drug in systemic circulation.
- Vesicular drug delivery is an efficacious method for reducing the drug toxicity and targeting to the site of action.
- This system improves the bioavailability principally in case of the poorly aqueous soluble drugs.
- In this systems both the hydrophilic and lipophilic drugs are embodied.

- It sustains the release of drugs by delaying the time of elimination through they are rapidly metabolizable.
- They overcoming the problems regarding stability, solubility and degradation of the drug.
- It acts as drug reservoir by encapsulating the drugand overcoming the problems of conventional dosageforms.
- These carriers correspond to the structure and function of biomolecules and hence are biocompatible and biodegradable.
- The vesicular carrier systems have observed a number of applications in various fields (9)

PHARMACOSOMES:

Pharmacosomes are part of the novel drug delivery system. They were first introduced by vaizoglu and Speriser in 1968. 10 Pharmacosomes are determined as the colloidal dispersions, drugs covalently bound to the lipids, and may exists as ultra fine vesicular, micellar, or hexagonal aggregates, on the basis of the chemical structure of the drug-lipid complex. The system is composed by linking a drug (pharmakon) to a carrier (soma), so they termed as “Pharmacosomes”.The drugs are presentin a dispersion form in these lipoidal drug delivery system conjugated by electron pair sharings and electrostatic hydroxyl groups, is converted to an ester with the help ofthe hydroxyl moiety of the lipid, resulting in the formation of a prodrug. A spacer chain may or may not be used for this purpose. The prodrug possesses both hydrophilic and lipophilic properties. Despite these properties, prodrugs havethe capability to reduce interfacial tension, increase the area of contact, and hence improve bioavailability. They aid the deportation through the cell membrane, cell wall, and tissues. If the concentration is increased beyond a level, it may exist in an intermediate state between liquid and crystal. On contact with water,

these prodrugs assemble into a single or multiple layers resulting in the formation of pharmacosomes. (10,11,12,13)

Salient Features of Pharmacosomes

- The physical and chemical traits of the conjugate control the stability of the whole system.
- As they consist of both water-loving and fat-loving properties, they have an ease of passing through the cell membrane, walls, or tissues either by the action of endocytosis or exocytosis.
- The rate of degradation relies on size, nature of functional group present in the drug molecule, fatty acid chain length in lipids, presence, or absence of spacer. All these factors can be varied to optimize in vivo pharmacokinetic behaviour.
- They can be administered via topical, oral, extra- or intravascular route. (14,15,16,17)

Advantages of pharmacosomes:

- When compared with other categories of lipid based delivery systems, pharmacosomes exhibit better results in many ways.
- The drug-lipid complex depends upon the phase transition temperature but independent on rate of release as it is covalently bounded to the lipid.
- No leaching will occur as drug is bounded to the lipid by covalent bonding.
- Delivers drug at the specific site and site targeted.
- By enzymatic methods like hydrolysis drug is released from the lipid polymer.
- The metabolism of the drug depends on the spacer, length of chain in lipid, functional groups and size of the drug during its absorption.
- They reduce the cost of therapy.
- They are suitable for the both lipophilic and hydrophilic drugs.
- The aqueous solution of the amphiphiles exhibits concentration dependent aggregation.
- The drug and carrier are covalently linked together so, entrapment efficiency is high and predetermined.
- Drug release of pharmacosomes is by hydrolysis.
- They improve the bioavailability majorly in case of poorly soluble drugs.
- They reduce the adverse effects and toxicity.
- In pharmacosomes, there is no need to remove the untrapped drug when compared to

liposomes where the free drug should be removed.

- Drugs like bupranolol hydrochloride, pindolol maleate, acyclovir, taxol, etc by using of pharmacosomes drug delivery has therapeutic performance has been improved. (18,19,20)

Disadvantages of pharmacosomes:

- Water insoluble drugs are encapsulated relatively in a less hydrophobic region within membrane bilayer rather than relatively large surface area.
- The storage of pharmacosomes undergoes fusion and aggregation as well as chemical hydrolysis. (21,22,23,24)

Components of Pharmacosomes:

Drugs

Any drug containing active hydrogen atom (-COOH, -OH, -NH₂, etc) can be esterified with the lipid, with or without spacer chain. Facilitates membrane, tissue, cell wall transfer in the organisms is due to its amphiphilic nature.

Solvents

They should be high pure and volatile in nature, and should be selected based on the intermediate polarity for their preparations.

Lipids

Phospholipids are the major components of biological membrane; majorly two types of phospholipids are used namely phosphoglycerides and sphingolipids.

The most common type of phospholipids is Phosphatidylecholine moiety.

Phosphatidylecholine is an amphiphilic molecule in which a glycerol bridges links a pair of hydrophobic acylhydrocarbon chains with hydrophilic polar head group phosphocholine. (25,26)

8. Ideal drug candidates for preparation of pharmacosomes:

BCS class II and IV drugs can be successfully loaded into pharmacosomes so as to increase their solubility and permeability.

Applications of pharmacosomes

1. Pharmacosomes provides a wider stability profile and greater shelf life.
2. Pharmacosomes have the capacity to augment drug absorption and its transport. Using response surface design, Yue et al. and colleagues optimized

the formulated geniposide pharmacosomes and examined their attributes. The ratio of phospholipid to drug, temperature of reaction mixture and concentration of drug were found to be 3, 50 °C and 5.5mg/mL, respectively.

3. Pharmacosomes can enhance the rate of permeation by improving the membrane fluidity. The transition temperature of vesicles in the form of vesicles and micelles might pose an evident effect on vesicular interaction with biomembrane, hence improving the transfer of drug across membrane.

4. Khare demonstrated the prominent effect of cascade fusion system of pharmacosomes at appropriate temperature on drug targeting in an organism by applying heating and cooling phenomenon on tissues.

5. Pharmacosomes have achieved a new level by enhancing therapeutic effects of several drugs like pindolol derivative, taxol, bupranolol acid derivative, cytarabine, amoxicillin, dermatansulphate.

6. Pharmacosomes are the amphiphilic lipid vesicular system, can be used for the development of novel ophthalmic dosage forms. Amphiphilic prodrug forms pharmacosomes, when diluted with tear and modify corneal drug transport and release profile.

7. Pharmacosomes have greater degree of selectivity for action on specific target cells. Raikhman et al. described pharmacosomes as building particles capable in the transport of biologically active substances including nucleic acids and proteins. (27)

Permeability Enhancement using vesicular drug delivery systems Pharmacosomes:

Poor aqueous solubility (dissolution) or permeability (across the biomembranes) of drugs are the major factors which govern bioavailability of drugs. During the course of drug discovery and development of dosage form the solubility and permeability are the key issue and for the same the drugs are classified in different classes on the same basis in Biopharmaceutical Classification System (BCS). The phytoconstituents may have the solubility (dissolution in aqueous media/gastro intestinal fluid) rate limited or the permeation rate limited absorption from the oral route and topical route. For improving solubility various techniques like solvent deposition, micronization, solid dispersion, supercritical fluid process, use of surfactants, use of salt forms, complexation etc.

have been investigated. Out of these, the complexation technique has been studied exhaustively to improve the solubility and the dissolution of poor water soluble drugs. In particular the lipid complexation improves the solubility as well as the permeability, due to the formation of an amphiphilic drug-lipid complex. Moreover, by virtue of their ability to form a protective coat over the mucosa, the lipid complexes have also been reported to reduce the gastric and hepatic toxicities of drug molecule 6-8. The lipid complexes are prepared with phosphatidylcholine. PC is an integral part of the cell membrane and exists in zwitterionic form. PC is not only a passive carrier for drug delivery but is itself a natural component with well investigated and reported clinical efficacy for various liver diseases. These amphiphilic drug-lipid complexes are stable and more bioavailable drug delivery systems with low interfacial tension between the system and the GI fluid thereby improving the permeation of drugs across the biomembranes. (28,29)

Preparation of pharmacosomes:

Initially for the formation of pharmacosomes, there is a need of drug-lipid conjugate. For this purpose, the salt form of the drug is converted into the acidic form to expose the functional hydrogen atom to form a complex. The aqueous solution of the drug is acidified, extracted using chloroform, and subsequently recrystallised. Then equimolar phospholipid concentration is taken and dissolved in an organic solvent, which is then evaporated under vacuum at a definite temperature. The complex is then collected as a dry residue after placing it in a desiccator overnight.

Solvent Evaporation Technique:

a. Hand-shaking method

→ In the hand-shaking method, both the drug and lipid shell be mixed in the round bottomed flask.

→ The organic solvent is evaporated by using rotary vacuum evaporator at room temperature, results in formation of a thin film of deposition on the walls.

→ The dried film is then hydrated with buffer and rotated in one direction with hand which results in the formation of vesicular suspension.

b. Rotary evaporator (Figure 5)




Figure 2 Applications of vesicular carrier systems.




Figure 3 Structure of Pharmacosome.




Figure 4 Forms and Components of Pharmacosomes

Ether injection method

- The drug-lipid complex is dissolved in specified volume of ether.
- Then the above mixture is slowly injected into a heated buffer solution, resulting in the formation of the vesicles.
- The nature of vesicle especially the shape depends on the concentration.
- The variety of structures may be formed that are, round, cylindrical, disc, cubic, or hexagonal type depending on the amphiphilic state.

Anhydrous co-solvent lyophilization method

- Drug and phospholipids are dissolved in solution of dimethylsulfoxide containing glacial acetic acid.
- Then the above mixture is agitated to get clear liquid and then freeze-dried overnight at condenser temperature.
- The complex obtained is flushed with nitrogen and stored at 4°C.

Supercritical fluid process

- This method is known as solution enhanced dispersion by complex supercritical fluid.
- Drug and lipid complex are premixed in a supercritical fluid of carbon dioxide, then high super saturation is obtained by passing through the nozzle mixture chamber.
- The turbulent flow of solvent and carbon dioxide results in fast mixing of dispersion leading to the formation of pharmacosome.

Solvent evaporation method

- In the solvent evaporation method of preparing the pharmacosomes, the drug is first acidified so that the active hydrogen might be available for complexation.
- The drug acid is then extracted into chloroform and subsequently recrystallized. The drug-PC complex is prepared by associating drug acid with PC in various molar ratios.
- The accurately weighed PC and drug acid are placed in a 100 ml round bottom flask and dissolved in sufficient amount of dichloromethane.
- The mixture is refluxed for one hour. Then the solvent is evaporated off under vacuum at 40 °C in a rotary vacuum evaporator.
- The dried residues are then collected and placed in vacuum desiccator for complete drying.

Recent approaches

- A biodegradable micelle forming drug conjugate was synthesized from the polymer consisting of polyxyethylene glycol and polyaspartic acid with a Adriamycin which is hydrophobic in nature.
- Diluting the micelle without the active constituent getting precipitated in the monomeric drug conjugate.
- Diluting lyotropic liquid crystals of amphiphilic drug by Muller-Goymann and Hamann.¹⁷
- Phosphatidylethanolamine with various molar ratios of Phosphatidylcholine and cholesterol which significantly enhanced cytoprotection by encapsulating amoxicillin Singh et al. formulated “vesicular constructs” using aqueous domain. (30,31,32,33)




Figure 5 Rotary Evaporator Method




Figure 6 Supercritical Fluid Process




Figure 7 Ether Injection Method

Characterization of pharmacosomes

1) Complex determination

Using correlation spectrum the formation of both conjugate and complex can be contingent upon inspecting with that of discrete constituents and also with their mixture using FTIR spectrum.

2) Surface morphology

The surface morphology can be predicted using Scanning Electron Microscopy (SEM) or Transmission Electron Microscopy (TEM). The shape and size of pharmacosomes are prone to variations by some variables such as rotation speed, vacuum applied, Purity grade of phospholipids or the method used.

3) Drug entrapment

To know the amount of drug present in the drug complex estimated quantity of pharmacosomes were transferred into a suitable flask containing known volume of solvent in which drug is soluble. Mix the above contents thoroughly

or sonicate, leave the contents for 24 hrs without disturbing and estimate the drug present by using UV spectroscopy or HPLC.

4) The Yield of drug “Present as a Complex” (%)

The prepared pharmacosomes are dispersed insufficient dichloromethane (5 ml/mg furosemide-SPC). The complex and phospholipids both were easily checked up in the dichloromethane or any other solvent in which drug is insoluble. The drug non-complexes is sedimented and separated to assay. The yield of drug “present as a complex (%) is defined using following formula equation,

$$\text{The yield} = \frac{a-b}{a} \times 100\%$$

Where a is the content of drug “present as a complex”, b is the content of drug “no-present as a complex” in the complex.

5) Determination of the Content of drug in Phospholipids Complex

The contents of drug in the complex are determined spectrophotometrically. A powder of 10 mg of the complex equivalent to the drug is dissolved in 10 ml of acetone and stirred for 2 h on a magnetic stirrer. The absorption of drug in the complex is determined by making suitable dilution and, measuring the absorbance at specified wavelength.

6) Solubility

Solubility is determined by placing the known amount of phospholipid complex in a screw capped penicillin bottle containing aqueous phase buffer solution of varying pH (2-7.4) and organic phase like 1- Octanol with continuous shaking at a temperature of 37°C for 24hrs. Then both the layers will be separated and samples were analyzed using HPLC or UV spectrophotometer.

7) Solubility of Pharmacosomes Complexes

Pharmacosomes complexes solubility was found out by preparing saturated solutions in various buffers at 37°C ± 0.5°C and continually shaken into mechanical orbital shaker (Remi mechanical shaking incubator, Bombay) up to 24 hrs. Samples are to be withdrawn and filtered through a 0.45 µm membrane filter (Millipore, India) followed by dilution and analyzed spectrophotometrically.

8) Partition Coefficient

Partition Coefficient determination of pharmacosomes was carried out by adding required quantity of pharmacosomes equivalent to drug, to a series of 10mL water solutions in sealed glass containers at 25°C, respectively. Each experiment is then executed in triplicate for each term. All the liquids are agitated for 24 h and centrifuged to remove excessive residues (15 min, 8000 rpm), respectively. Each liquid is added 10mL n-octanol and agitated for 24 h. And so they are centrifuged at 8000 RPM for 15 min, respectively. The water phase and n-octanol phase are separated. The water phase and n-octanol phase are filtrated through a 0.45µm membrane, respectively. Suitable dilution are made, the concentrations of drug is measured.

8) Drug lipid compatibility

Differential scanning electron microscopy is a thermo analytical technique used to determine drug-lipid compatibility and their interactions. Thermal response is studied by using separate sample and heating them in a sample pan, which is

closed. The nitrogen gas is plugged, and the temperature is maintained in a definite range with a specific heating rate

9) Crystal state measurement

The crystal nature of the drug can be determined by using X-ray diffraction technique. The tube voltage and tube current can be regulated in the X-ray generator. Copper lines may be used as the source of radiations. The overall integrated intensity of all reflection peaks are projected by area under curve of X-ray diffraction pattern that specifies the specimen characteristics.

10) Dissolution studies

Dissolution studies in vitro are done by using various models available using different buffers, then the results obtained are estimated on the basis of activity of the drug.

11) In vitro drug release rate

The in vitro drug release rate is estimated by reverse dialysis bag technique. In this method pharmacosomes are introduced inside the dialysis bag and the receiver phase is placed outside. Dialysis bag containing the continuous phase and they are suspended in a vessel containing the donor phase and stirred at predetermined time intervals, each dialysis bag is removed and the contents are analyzed for drug release. An advantage of this technique is increase in the membrane surface area available for transport from the donor to receptor compartment. Another advantage of this technique is the increased efficiency in terms of staffing as a consequence of reduction in number of step.

12) Stability of pharmacosomes

Although pharmacosomes do not undergo destabilisation of lipid bilayer membrane as that of liposomes because the drug is covalently bound to the phospholipid but the two major degradation pathway i.e. oxidation and hydrolysis results in reduction of shelf life of phospholipid based vesicles. In comparison to saturated fatty acids, unsaturated fatty acyl chains are more susceptible to oxidation. Phospholipid peroxidation can be reduced by utilizing pure form of phospholipids, storing them at a lesser temperature, protecting them from exposure to light and oxygen, and adding antioxidants. Matrix-assisted laserdesorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS), liquid chromatography mass spectrometry (LCMS), and HPLC were used to study the degradation of the drug-phospholipid combination. The appearance

phospholipid due to hydrolysis of prodrug indicates that the prodrug has been subjected to enzymatic

degradation.(34,35,36,37,38)

Table 1 Comparison of various methods of pharmacosomes preparation of various drugs and their outcomes

S.no	Drug	Polymer	Solvent	Bonding	Technique used	Results	Final Product
1	Geniposide	Phospholipids	Tetrahydrofuran	Hydrogen, van der Waal forces	Vacuum evaporation method	Lipid solubility character of Geniposide was increased	Dry powdered pharmacosomes
2	Naproxen	Soya lecithin	Diethyl ether, ethanol, acetone	Covalent bond	Ether injection method	Solubility enhanced and achieved controlled drug release	Pharmacosomes gel
3	Aspirin	Soya phosphatidylcholine	Dichloromethane	Covalent bond	Solvent evaporation	Improved drug delivery controlled drug delivery	Pharmacosomes
4	Furosemide	Soya phosphatidylcholine	Methyl alcohol	Hydrogen bond	Vacuum evaporation	Release and permeation increased	Pharmacosomes
5	Ketoprofen	Soya phosphatidylcholine	Dichloromethane	-	Solvent evaporation	Improved solubility, dissolution profile	Pharmacosomes
6	Etodolac	Soya lecithin	Acetone, dichloromethane, methanol	-	Thin film hydration	Increased solubility, entrapment efficiency and sustained release	Pharmacosomes gel
7	Rosuvastatin	Soya lecithin	Chloroform, dichloromethane	-	Solvent evaporation	Sustained drug release and improved bioavailability	Pharmacosomes

8	Ibuprofen	Phosphatidylcholine	Dichloromethane, chloroform	-	-	Increased bioavailability	Pharmacosomes
9	Bupranolol	Soya lecithin		Covalent bond		Enhanced effect on intraocular pressure and enhance lymph transport.	Pharmacosomes
10	Levodopa	Soya lecithin	Tetrahydrofuran	Covalent bond	Solvent evaporation	Enhanced brain uptake	Pharmacosomes
11	Diclofenac	Phosphatidylcholine	Dichloromethane	Covalent bond	Solvent evaporation	Improved solubility and drug loading	Pharmacosomes
12	Didanosine	Soya lecithin	Chloroform, acetone, methanol		Tetrahydrofuran injection method	Increased solubility, dissolution profile and bioavailability	Pharmacosomes

Table 2 Comparison of various vesicular drug delivery systems

S.no	Type	Ingredients	Method	Advantages	Disadvantages
1	Pharmacosomes	Solvents, phospholipids	Sonication, Hand shaking method, Ether injection, Anhydrous cosolvent lyophilization.	No leaching will occur as drug bounded to the lipid by covalent bonding, Delivers the drug at the site specific and site targeted, They reduces the cost therapy, Reduces the adverse effects and toxicity	The storage of pharmacosomes undergoes fusion, aggregation and hydrolysis, Water insoluble drugs are encapsulated relatively in a less hydrophobic region within membrane bilayer or relatively large surface area
2	Liposomes	Phosphatidylcholine, cholesterol, sphingolipids, steroids, polymeric materials.	Sonication method, French pressure cell, Freeze-thawed liposomes, Lipid film hydration by hand	Suitable for delivery of hydrophilic, hydrophobic drugs. Biocompatible, suitable for controlled drug delivery,	High production cost, leakage (or) fusion of encapsulated drug phospholipid

			shaking or freeze drying.	localized action in particular tissue.	undergo hydrolysis (or) oxidation reaction, short half life and low solubility
3	Niosomes	Solvents, phospholipids	Sonication, Microfluidication, Hand shaking, Ether injection, Reverse phase evaporation, Bubble method, Active transport.	Stable, increase the stability of entrapment drug, Improved oral bioavailability of poorly absorbed drugs, PEG-glucose conjugates on the surface of niosomes significantly improved tumor targeting of an encapsulated paramagnetic agent	Time consuming, In efficient drug loading, Requires specialized equipments.
4	Transferosomes	Phospholipids, surfactants, alcohols, buffering agents	Thin film hydration method, Modified hand shaking method, Vortexing-sonication method, Suspension, homogenization process, Aqueous lipid, suspension process, Centrifugation process.	High entrapment efficiency in case of lipophilic drugs, They protect the encapsulated drug from metabolic degradation.	They are chemically unstable because of predisposition to oxidative degradation, Their formulation and manufacturing expensive.
5	Aquasomes	Polymers, ceramic core	Preparation of core, Carbohydrate coating, Immobilization of drugs	Aquasomes preserves the conformational integrity and biochemical stability of bioactive molecules, Aquasomes exhibit physical properties of colloids, Aquasomes avoids reticuloendothelial clearance or degradation by other environmental	-

				challenges, Aquasomes suspensions contain colloidal range biodegradable nanoparticles, they are more concentrated	
6	Phytosomes	Phospholipids , commercial products, flavonoids	Solvent evaporation, Salting out, lyophilization , Rotary evaporation , Anti solvent precipitation .	As the efficacy increases the dosage requirement is also reduced They have better stability, By increasing solubility of bile to herbal origin Phytoconstituents, Phytosomes enhance the liver targeting, Time period of action is increased	Duration of action is short, Phytoconstituents is rapidly eliminated from Phytosomes.

II. CONCLUSION:

In pharmacosomes drug is bound to the polymer by covalent, van der Waal and hydrogen bonding. The drug will be released will by hydrogen bonding. Both the lipophilic and hydrophilic drugs can be suitable candidates, by covalent bonding with the polymer shows increase in entrapment efficiency. Pharmacosomes reduce toxicity and can improve therapeutic performance of drug. A biodegradable micelle forming drug conjugates increasing hydrophilicity of drug, Whereas change in the ratio of polymers show enhance cytoprotection by formulation of “vesicular constructs “using aqueous domain. Despite having disadvantages of getting fused, aggregated, they still serve as a vital tool for targeting and sustained drug release. Hence, pharmacosomes have immense potential in improving the drug delivery in case of both natural and synthetic active constituents.

REFERENCES:

- [1]. Vaizoglu MO, Speiser PP. Pharmacosomes-A novel drug delivery system. *ActaPharmaceuticaSinica*, 1986; 23:163 -172.
- [2]. DoijadRajendra C, Bhambere Deepak S, ManviFakirappa V, DeshmukhNarendra V. Formulation and characterization of vesicular drug delivery system for Anti-HIV drug. *Journal of Global Pharma Technology*, 2009; 1:94-100
- [3]. S. Swarnalata, R. Rahul, K. Chanchal Deep, and S. Shailendra, “Colloidosomes an advanced system in drug delivery,” *Asian Journal of Scientific Research*, vol. no. 1, 2011:1-15.
- [4]. Drug carrier Wikipedia, sevenson, sonke , carrier based drug delivery, 2004.
- [5]. M. Gangwar, Singh R, RK. Goel, G. Nath. Recent advances in various emerging vesicular systems: An Overview. *Asian Pacific Journal of Tropical Biomedicine*, 2011; 33:848.
- [6]. AD. Bangham, MM. Standish, JG. Watkins. The action of steroids and streptolysin S on the permeability of phospholipid structures to cations. *J MolBiol*, 1965; 13: 238.
- [7]. Biju SS, Talegaonkar S, Mishra PR, Khar KR. Vesicular System: An overveiw. *Indian J. Pharm Sci*, 2009; 71(4):421-427.
- [8]. Ogihara U, Sasaki T, Toyama H, Odak SM, Nishigori H. *Cancer Detect Prev*, 1997; 21(6):490.
- [9]. Kavitha D, Naga Sowjanya J, Shanker P. Pharmacosomes: An emerging vesicular system. *International Journal of*

- Pharmaceutical Sciences Review and Research, 2010; 5(3):168-171.
- [10]. Vaizoglu O, Speiser P P. Pharmacosomes: a novel drug delivery system, *Acta Pharm Suec.*, 1986; 23:163-72.
- [11]. Bombardelli E, Spelta M. Phospholipidpolyphenol complexes: a new concept in skin care ingredients, *Cosm Toil.*, 1991; 106(3):69- 76.
- [12]. P. H. Sharma, P. V. Powar, S. S. Sharma. Pharmacosomes: A novel drug delivery system. *The pharma innovations journal* 2014; 3(10):94-100.
- [13]. Lawrence MJ. Surfactant Systems: Their use in drug delivery. *ChemSoc Rev*, 1994; 23:417-424.
- [14]. A. Steve, "Lipophilic drug derivatives for use in liposomes," US Patent S, 534, 499, (C1 S14-25, A61K31/70), 1996.
- [15]. I. Taskintuna, A. S. Banker, M. Flores-Aguilar et al., "Evaluation of a novel lipid prodrug for intraocular drug delivery: effect of acyclovir diphosphatemyristoylglycerol in a rabbit model with herpes simplex virus-1 retinitis," *Retina*, vol. 1997, 17(1):57-64.
- [16]. Solanki D, Patidar A, Kukde D, Pharmacosomes – a review, *International Journal of Pharmacy, Eng and Life Sci.* 2016; 12(3):70-78.
- [17]. Muller-Goymann CC, Hamann HJ. Pharmacosomes: Multilamellar vesicles consisting of pure drug. *Eur J Pharm Biopharm.* 1991; 37: 113-117.
- [18]. A. Singh and R. Jain, "Targeted Vesicular Constructs for cryoprotection and treatment of H. Pylori infections," US Patent 6576, 2003,625.
- [19]. Rewar S, Mirdha D, Rewar P. A vital role of pharmacosome's on controlled and novel drug delivery, *Asi J of Res in Biol and Pharm Scienc.* 2014, 2(4), 163 - 170.
- [20]. D. NagasamyVenkatesh, K. Kalayani, K. Tulasi, V. S. priyanka, SK.A. Ali, S.S. Kumar."Pharmacosomes: A potential vesicular drug delivery system. *IJPSSDR*, 2014; 6(2):90-94.
- [21]. Semalty A, Semalty M, Singh D and Rawat M S M. "Development and physicochemical evaluation of pharmacosomes of diclofenac," *ActaPharmaceutica*, 2009; 59(3):335-344.
- [22]. Semalty A, Semalty M, Rawat B S, Singh D, Rawat M S M. Pharmacosomes: The lipid based novel drug delivery system, *Expert Opinion on Drug Delivery*, 2009; 6:599-612.
- [23]. Raikhman L M, Moshkovskii Y S and Piruzyan L A. "Pharmacosome concept: a new approach to drug preparation," *Pharmaceutical Chemistry Journal*, 1978; 12(4):431-434.
- [24]. Semalty A, Semalty M, Rawat B S, Singh D, Rawat M S M. Development and evaluation of pharmacosomes of aceclofenac, *Ind J PharmaSci*, 2010; 72:576-81.
- [25]. Han M, Chen J, Chen S and Wang X. "Preparation and study in vitro of 20(S) protopanaxadiol pharmacosomes," *China Journal of Pharmaceutics*, 2010; 35:842-846.
- [26]. Ping A, Jin Y, Da-Wei C. Preparation and in-vivo behavior of didanosine pharmacosomes in rats. *Chin J Pharm*, 2005; 3:227- 235.
- [27]. Zhang Z R, Wang J X and Lu J. "Optimization of the preparation of 3', 5'-dioctanoyl-5-fluoro2'-deoxyuridine pharmacosomes using central composite design," *YaoxueXuebao*, 2001; 36(6):456-61.
- [28]. Yi-Guang J, Ping A I, Miao L I and Xin-Pu H. "Preparation and properties of Acyclovir pharmacosomes," *Chinese J Pharma.*, 2005; 36(10):617-620.
- [29]. Semalty A, Semalty M, Singh D and Rawat M S M. "Preparation and characterization of phospholipid complexes of naringenin for effective drug delivery," *J Inclusion Phen and MacrocChem*, 2010; 67(3):253-260.
- [30]. Patil S D Chatap V K, Patil P L. In-vitro, ex-vivo characterization of Furosemide bounded pharmacosomes for improvement of solubility and permeability. *AdvPharmacol Pharm.* 2014; 2(5):67-76.
- [31]. Harikumar S L, Kaur A, Sharma N. Design and development of Ketoprofen pharmacosomes for oral drug delivery. *Pharmacophore*, 2013; 4(4):111-119.
- [32]. Patel R A, Nanda A, Saini S. Design and development of bupranolol. *Int J Drug Dev Res.* 2010; 2(2):247-252.
- [33]. Vaizoglu M O, Speiser P P. Preparation, in-vitro and in-vivo characterization of pindololpharmacosomes. *Int J Health Res.* 2009; 2(3):225-232.
- [34]. Yep P F, Zheng Q, Bin W, Yang M, Wang M S, Zhang H Y. Process optimization by



- response surface design and characterization study on Geniposide pharmacosomes. *Pharm Dev Technol.* 2012; 17(1):94-102.
- [35]. Guang J Y, Ping A I, Miao L I, Xin-Pu H. Preparation and properties of Acyclovir pharmacosomes. *Chin J Pharm.* 2005; 36(10):617-620.
- [36]. Patel V, Agrawal Y K. Preparation of Zidovudine pharmacosome: Enhancement in in-vivo anti tumour activity. *J Global Trends Pharm Sci.* 2011; 2(2): 131-148.
- [37]. Kamalesh M, Baviskar D, Wagh K, Baviskar K. Formulation and evaluation of pharmacosomes of Ketoprofen. *Indo Am J Pharm Res.* 2014; 4(3):1363-1368.
- [38]. Kumar PT., Mishra J., Podder A., Design, Fabrication and evaluation of Rosuvastatin pharmacosome- a novel sustained drug delivery system, *European Journal of Pharmaceutical and medical research*, 2016; 3:4:332-350.